In a strategic move to focus on patented products, high-price and high-margin drugs, GlaxoSmithKline Pharmaceuticals has decided to bring down the number of brands in India to about 20 from 130, reported Business Standard.

“We have decided to have fewer brands. This not only simplifies our operations but also enables us to put our energy where it matters,” Annaswamy Vaidheesh, managing director for India, said.

The UK-based drugmaker which has patented brands such as Calpol, Augmentin, Zinetac among others said it is planning on bringing more intellectual property products to India, especially in the respiratory and anti-infective space, according to the report.

It added that the top 10 brands of the company contribute almost 52.1 percent of GSK India’s sale.

In the last one year, the company has reduced the number of brands from 130 to 70, said the report, adding that the firm will launch brand extensions whenever needed and focus on bringing in patented products.